AngioDynamics, Inc. (NASDAQ:ANGO) Holdings Boosted by US Bancorp DE

US Bancorp DE boosted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 1,938.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,705 shares of the medical instruments supplier’s stock after purchasing an additional 6,376 shares during the period. US Bancorp DE’s holdings in AngioDynamics were worth $61,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANGO. R Squared Ltd purchased a new position in AngioDynamics during the 4th quarter worth approximately $49,000. Quarry LP grew its holdings in shares of AngioDynamics by 40.9% during the 3rd quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 2,471 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of AngioDynamics by 21.3% during the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock valued at $147,000 after acquiring an additional 2,832 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of AngioDynamics during the 3rd quarter valued at $280,000. Finally, Quest Partners LLC purchased a new position in shares of AngioDynamics during the 3rd quarter valued at $285,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price target on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 10th.

AngioDynamics Stock Up 6.4 %

AngioDynamics stock opened at $9.59 on Tuesday. The company’s fifty day simple moving average is $10.83 and its 200-day simple moving average is $8.65. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $13.50. The stock has a market cap of $388.07 million, a P/E ratio of -1.70 and a beta of 0.56.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. During the same quarter in the previous year, the business earned ($0.05) EPS. AngioDynamics’s quarterly revenue was down .1% compared to the same quarter last year. On average, equities research analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is owned by company insiders.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.